IL-15 Enhanced NK Cell Therapy for Solid Tumors

Sponsor
Genovn Therapeutics (Suzhou) Co., Ltd.
Study ID
NCT07621471
Phase
EARLY_PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Metastatic Cancer
  • Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • IL-15 enhanced engineered NK cells — DRUG
    Genetically engineered NK cells expressing IL-15. Administered intravenously. See protocol for dose details.
  • IL-15 Enhanced Engineered NK Cells — BIOLOGICAL
    Genetically engineered NK cells expressing IL-15

Study Details

A single-arm, Phase 1 study evaluating safety, tolerability, and preliminary efficacy of IL-15 enhanced engineered NK cells in patients with refractory relapsed or metastatic solid tumors.

Key Dates

First listed
Jun 2, 2026
Start date
Jul 1, 2026
Status verified
May 2026
Primary completion
Dec 31, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
12 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: IL-15 Enhanced Engineered NK Cells
    Single arm. Patients receive IL-15 enhanced engineered NK cells after lymphodepletion chemotherapy.

Primary Outcome Measure

Incidence of Dose-Limiting Toxicity (DLT) [ Time Frame: Within 28 days after first infusion ]

Related Studies